Kuromiya Akemi | Genomic Science Laboratories Dainippon Sumitomo Pharma Co. Ltd.
スポンサーリンク
概要
関連著者
-
Ono Yoshiyuki
International Business Management Dainippon Sumitomo Pharma Co. Ltd.
-
MATSUMOTO Takafumi
Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd.
-
KUROMIYA Akemi
Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd.
-
BRIL Vera
Department of Medicine, University of Toronto EN11-209, Toronto General Hospital
-
Bril Vera
Department Of Medicine University Of Toronto En11-209 Toronto General Hospital
-
Kuromiya Akemi
Genomic Science Laboratories Dainippon Sumitomo Pharma Co. Ltd.
-
Matsumoto Takafumi
Pharmacology Research Laboratories Dainippon Sumitomo Pharma Co. Ltd.
-
Nakamura Keiji
Analytical Chemistry Center Nichiei Sangyo Co. Ltd.
-
KURONO Masuo
Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd.
-
Kurono Masuo
Chemistry Research Laboratories Dainippon Sumitomo Pharma Co. Ltd.
-
Toyosawa Kaoru
Safety Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd.
-
Toyosawa Kaoru
Safety Research Laboratories Dainippon Sumitomo Pharma Co. Ltd.
-
UEDA Yoshinaka
Safety Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd.
-
NAKAMURA Keiji
Nichiei Sangyo Co., Ltd., Analytical Chemistry Center
-
Ueda Yoshinaka
Safety Research Laboratories Dainippon Sumitomo Pharma Co. Ltd.
著作論文
- Improvement of Motor Nerve Conduction Velocity in Diabetic Rats Requires Normalization of the Polyol Pathway Metabolites Flux
- Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats
- Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Reduces Sorbitol Levels and Improves Motor Nerve Conduction Velocity in Streptozotocin-Diabetic Rats